TNG908
Phase 2Small molecule
TNG908 is one of 3 small molecule programs targeting MTAP-deleted Solid Tumors. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in MTAP-Deleted Solid Tumors
#DrugCompanyPhaseTrials
1BAY 987519
BayerPreclinical
TNG908
TTango Therapeutics, Inc.
Phase 2
TNG462
TTango Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TNG908. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTango Therapeutics, Inc.